
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
On June 27, 2026, WVE-N531 — Wave Life Sciences Ltd. (Duchenne Muscular Dystrophy) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved +0.0% in the window around the event. It had already run -8.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
CatalystAlert called this one neutral (+0.6% expected); the stock actually moved +0.0%. Model confidence at the time: 40%.
See the full scored track record